In a patient refusing benzodiazepines during alcohol withdrawal detoxification, is it appropriate to add levetiracetam (Keppra) or gabapentin?

Benzodiazepine Alternatives in Alcohol Withdrawal

Benzodiazepines remain the gold standard for alcohol withdrawal syndrome, and neither levetiracetam (Keppra) nor gabapentin should be used as monotherapy replacements when a patient refuses benzodiazepines. However, if a patient absolutely refuses benzodiazepines, gabapentin has moderate evidence as an alternative, while levetiracetam lacks sufficient evidence for this indication.

The Evidence-Based Hierarchy

Benzodiazepines Are Standard of Care

The EASL 2018 guidelines explicitly state that benzodiazepines are the "gold standard" treatment for alcohol withdrawal syndrome given their proven efficacy for reducing withdrawal symptoms AND preventing seizures and delirium tremens 1. The WHO 2011 guidelines similarly recommend benzodiazepines as front-line medication for managing alcohol withdrawal, specifically for alleviating discomfort and preventing/treating seizures and delirium 2. The 2020 AASLD guidance reinforces this standard 3.

Why This Matters for Morbidity and Mortality

Alcohol withdrawal can progress to delirium tremens, seizures, coma, cardiac arrest, and death 1. The primary goal is preventing these life-threatening complications. Benzodiazepines have proven mortality benefit through seizure and delirium prevention—alternatives do not have this same level of evidence.

If Benzodiazepines Are Refused: Gabapentin Over Levetiracetam

Gabapentin: Moderate Evidence as Benzodiazepine-Sparing Agent

Gabapentin has the strongest evidence among alternatives, though it should ideally be used WITH benzodiazepines, not instead of them:

• A 2025 study showed gabapentin-based protocols reduced benzodiazepine exposure by 57% (9.7 mg vs 22.8 mg lorazepam equivalents) with similar clinical outcomes 4
• A 2018 Mayo Clinic protocol review of 77 patients showed no withdrawal seizures or transfers to higher care when using gabapentin for mild-to-moderate withdrawal 5
• A 2021 systematic review rated gabapentin as having "moderate" level evidence for reducing AWS severity, the highest rating among all benzodiazepine alternatives 6
• Multiple studies (2003,2018) demonstrate efficacy in mild-to-moderate withdrawal 7, 5

Practical dosing from the literature: 1,200-3,600 mg/day in divided doses, with typical starting doses of 300-600 mg TID 4, 5, 7

Levetiracetam: Insufficient Evidence

Levetiracetam (Keppra) is NOT appropriate for alcohol withdrawal management:

• The FDA labeling for Keppra makes NO mention of alcohol withdrawal as an indication 8
• Keppra is approved only for seizure disorders (epilepsy), not withdrawal seizure prevention
• One small 2010 observational study (131 patients) showed it was "efficacious and safe" for outpatient detoxification, but this was open-label with no control group 9
• A 2002 mouse study showed it normalized benzodiazepine withdrawal anxiety, but this is animal data for benzodiazepine withdrawal, not alcohol withdrawal 10
• The 2021 systematic review did NOT include levetiracetam among evaluated alternatives 6

The evidence gap is critical: While levetiracetam is used for status epilepticus after benzodiazepines fail 11, 12, this is fundamentally different from preventing alcohol withdrawal seizures. Alcohol withdrawal seizures occur due to GABA/glutamate imbalance from chronic alcohol exposure—levetiracetam's mechanism (synaptic vesicle protein SV2A modulation) is not targeted to this pathophysiology.

Critical Safety Concerns

The Seizure and Delirium Risk

Without adequate GABA-ergic coverage, patients remain at risk for:

• Withdrawal seizures (can occur 6-48 hours after last drink)
• Delirium tremens (mortality 5-15% if untreated)
• Autonomic instability leading to cardiac complications

Neither gabapentin nor levetiracetam has proven efficacy in PREVENTING these complications the way benzodiazepines do 1, 2.

Gabapentin-Specific Concerns

• Dependence potential: Gabapentin itself can cause physiologic dependence and severe withdrawal, requiring prolonged tapers (up to 18 months documented) 13
• Abuse potential: Increasingly recognized as a drug of misuse, particularly in patients with substance use disorders
• Not benign: The 2019 study showed gabapentin did NOT reduce benzodiazepine requirements in acute inpatient withdrawal 14

Levetiracetam-Specific Concerns

The FDA labeling warns of significant behavioral and psychiatric adverse effects 8:

• Behavioral disorders (aggression, irritability, hostility) in 11-38% of patients
• Mood disorders (depression, mood swings) in 6-13% of patients
• Psychotic symptoms including hallucinations and suicidal thoughts
• These effects could be catastrophic in an already agitated, withdrawing patient

The Clinical Algorithm When Benzodiazepines Are Refused

Step 1: Aggressive Counseling and Risk Disclosure

• Explain that benzodiazepines are the ONLY proven therapy to prevent death from alcohol withdrawal
• Document the refusal and that alternatives have inferior evidence
• Consider involving family, social work, or ethics consultation if patient lacks capacity

Step 2: Risk Stratification

High-risk patients (any of the following) REQUIRE benzodiazepines or inpatient monitoring:

• History of withdrawal seizures or delirium tremens
• CIWA-Ar score ≥15 (severe withdrawal) 1
• Heavy alcohol use (>8 drinks/day for men, >6 for women, prolonged duration)
• Significant comorbidities (liver disease, cardiac disease, malnutrition)
• Concurrent benzodiazepine or sedative use

These patients should NOT be managed with gabapentin or levetiracetam alone—they need inpatient care with benzodiazepines, even if involuntary commitment is required.

Step 3: For Mild-to-Moderate Withdrawal ONLY

If CIWA-Ar <15, no high-risk features, and patient has adequate support:

Gabapentin protocol (based on 4, 5):

• Gabapentin 300-600 mg TID (total 900-1,800 mg/day)
• Can increase to 1,200 mg TID (3,600 mg/day) if needed
• Continue for 5-7 days with daily monitoring
• Must have rescue benzodiazepines available (lorazepam 1-2 mg PRN for breakthrough symptoms)
• Daily CIWA-Ar scoring
• Thiamine 100 mg daily (oral) or IV if malnourished 1, 2

Do NOT use levetiracetam—insufficient evidence and concerning psychiatric side effects.

Step 4: Monitoring and Escalation Triggers

Immediate benzodiazepine administration or ED transfer if:

• CIWA-Ar rises above 15
• Any seizure activity
• Hallucinations or severe agitation
• Autonomic instability (HR >120, SBP >180, temperature >38.5°C)
• Patient cannot be monitored daily

Common Pitfalls to Avoid

1. Assuming gabapentin is "neuroprotective": It is not proven to prevent withdrawal seizures or delirium tremens
2. Using levetiracetam because it's an antiepileptic: Epilepsy seizures ≠ withdrawal seizures; mechanism matters
3. Underestimating withdrawal severity: When in doubt, use benzodiazepines
4. Outpatient management of high-risk patients: These patients need inpatient care regardless of medication preference
5. Forgetting thiamine: All alcohol withdrawal patients need thiamine to prevent Wernicke's encephalopathy 1, 2

The Bottom Line

The safest approach when a patient refuses benzodiazepines is intensive counseling to accept them, or inpatient monitoring where they can be administered if withdrawal worsens. If the patient has only mild withdrawal and refuses benzodiazepines despite counseling, gabapentin with close monitoring and available rescue benzodiazepines is the only alternative with any supporting evidence. Levetiracetam should not be used for this indication—it lacks evidence, has concerning psychiatric effects, and is not targeted to alcohol withdrawal pathophysiology.